| Field | Specification |
|---|---|
| Target | |
| Alternative names | Retinoic acid receptor RXR-alpha; Nuclear receptor subfamily 2 group B member 1; Retinoid X receptor alpha; RXRA; NR2B1 |
| UniProt # | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | E. coli-derived human RXRA recombinant protein (Position: A226-T462). |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Lyophilized |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
This rabbit polyclonal antibody detects retinoic acid receptor RXR-alpha (gene RXRA) in human, mouse and rat samples and is validated for ELISA, flow cytometry, ICC/IF, IHC and Western blot. The predicted molecular weight is 50.8 kDa, and the supplier reports an observed band at about 51–55 kDa.
RXRα (RXRA) is a nuclear receptor activated by 9-cis retinoic acid that acts as a shared dimerization partner for many other nuclear receptors, including RARs, PPARs, LXR and the vitamin D receptor. Depending on ligands and partners, these dimers recruit corepressors or coactivators to control genes in development, lipid metabolism and cell differentiation.
| Target | Retinoic acid receptor RXR-alpha (gene RXRA; UniProt P19793, human) |
|---|---|
| Host / Clonality / Isotype | Rabbit / Polyclonal / Rabbit IgG |
| Reactivity | Human, Mouse, Rat |
| Form | Lyophilized |
| Formulation | Per vial: 4 mg trehalose; 0.9 mg NaCl; 0.2 mg Na2HPO4; 0.05 mg NaN3 |
| Calculated MW | 50.8 kDa |
| Observed MW | 51–55 kDa |
| Storage | As supplied: −20 °C for up to 12 months from receipt. After reconstitution: 4 °C for up to 1 month, or aliquot and keep at −20 °C for up to 6 months. Avoid repeated freeze–thaw cycles. |
Validated Applications
| Western blot | 0.1–0.5 µg/mL |
|---|---|
| IHC (paraffin sections) | 0.5–1 µg/mL |
| Immunocytochemistry / Immunofluorescence | 2 µg/mL |
| Flow cytometry (fixed cells) | 1–3 µg/1×106 cells |
| ELISA | 0.1–0.5 µg/mL |
Samples with a confirmed band (WB): human HeLa cells, human COLO-320 cells, human A431 cells, human MCF-7 cells, human liver cancer tissue, rat heart tissue, mouse heart tissue.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 5–20% gradient SDS-PAGE under reducing conditions, 50 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 0.5 µg/mL overnight at 4 °C, HRP-conjugated secondary antibody at 1:10000, ECL detection.
Samples with confirmed staining (IHC): mouse liver tissue, rat liver tissue.
Recommended antigen retrieval: heat-mediated, in TE buffer (pH 9.0); citrate buffer (pH 6.0) can be used instead.
Conditions in the example images (IHC): heat-mediated antigen retrieval in EDTA buffer (pH 8.0).
Samples with confirmed staining (ICC/IF): A431 cells.
Samples with a confirmed signal (flow cytometry): A431 cells.
Immunogen
Recombinant human RXRA fragment (Ala226–Thr462), expressed in E. coli.
Reactivity Notes
The supplier lists reactivity with human, mouse and rat. UniProt places retinoic acid receptor RXR-alpha in the nucleus, cytoplasm and mitochondrion. Tissue expression noted by UniProt (human): Expressed in lung fibroblasts (at protein level). The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
